55 related articles for article (PubMed ID: 33356246)
1. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
Cheng H; Orr STM; Bailey S; Brooun A; Chen P; Deal JG; Deng YL; Edwards MP; Gallego GM; Grodsky N; Huang B; Jalaie M; Kaiser S; Kania RS; Kephart SE; Lafontaine J; Ornelas MA; Pairish M; Planken S; Shen H; Sutton S; Zehnder L; Almaden CD; Bagrodia S; Falk MD; Gukasyan HJ; Ho C; Kang X; Kosa RE; Liu L; Spilker ME; Timofeevski S; Visswanathan R; Wang Z; Meng F; Ren S; Shao L; Xu F; Kath JC
J Med Chem; 2021 Jan; 64(1):644-661. PubMed ID: 33356246
[TBL] [Abstract][Full Text] [Related]
2. Structure-based drug design, synthesis, and biological evaluation of novel 1,3,5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors.
Fu S; Liu J; Li C; Wei J; Yue H; Yang A; Wang K; Wu Y; Hou Y; Zhao Y
Bioorg Chem; 2023 Nov; 140():106738. PubMed ID: 37562315
[TBL] [Abstract][Full Text] [Related]
3. PI3K inhibitors are finally coming of age.
Vanhaesebroeck B; Perry MWD; Brown JR; André F; Okkenhaug K
Nat Rev Drug Discov; 2021 Oct; 20(10):741-769. PubMed ID: 34127844
[TBL] [Abstract][Full Text] [Related]
4. Discovery of (S)-N
Zhang Y; Gao J; Wu J; Liu S; Zhang X; Lv X
Bioorg Med Chem Lett; 2023 Oct; 94():129462. PubMed ID: 37652098
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
Ketcham JM; Harwood SJ; Aranda R; Aloiau AN; Bobek BM; Briere DM; Burns AC; Caddell Haatveit K; Calinisan A; Clarine J; Elliott A; Engstrom LD; Gunn RJ; Ivetac A; Jones B; Kuehler J; Lawson JD; Nguyen N; Parker C; Pearson KE; Rahbaek L; Saechao B; Wang X; Waters A; Waters L; Watkins AH; Olson P; Smith CR; Christensen JG; Marx MA
J Med Chem; 2024 Mar; 67(6):4936-4949. PubMed ID: 38477582
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel bivalent PI3K inhibitors for the potential treatment of cancer.
Xia L; Jiang L; Du T; Lin S; Xiong T; Peng S; Tian H; Zhang K; Wu D; Sheng L; Ji M; Chen X; Xu H
Bioorg Chem; 2023 Nov; 140():106814. PubMed ID: 37657197
[TBL] [Abstract][Full Text] [Related]
7. Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.
Down K; Amour A; Anderson NA; Barton N; Campos S; Cannons EP; Clissold C; Convery MA; Coward JJ; Doyle K; Duempelfeld B; Edwards CD; Goldsmith MD; Krause J; Mallett DN; McGonagle GA; Patel VK; Rowedder J; Rowland P; Sharpe A; Sriskantharajah S; Thomas DA; Thomson DW; Uddin S; Hamblin JN; Hessel EM
J Med Chem; 2021 Sep; 64(18):13780-13792. PubMed ID: 34510892
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs.
Zheng XM; Chen YS; Ban YJ; Wang YJ; Dong YX; Lei L; Guo B; Wang JT; Tang L; Li HL; Zhang JQ
Eur J Med Chem; 2023 Nov; 260():115754. PubMed ID: 37651880
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of 1,3,5-Triazines or Pyrimidines Containing Dithiocarbamate Moiety as PI3Kα Selective Inhibitors.
Tang J; Liu J; He X; Fu S; Wang K; Li C; Li Y; Zhu Y; Gong P; Zhao Y; Liu Y; Hou Y
ACS Med Chem Lett; 2023 Sep; 14(9):1266-1274. PubMed ID: 37736169
[TBL] [Abstract][Full Text] [Related]
11. A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors.
Shafiq M; Sherwani ZA; Mushtaq M; Nur-E-Alam M; Ahmad A; Ul-Haq Z
Mol Divers; 2024 Feb; ():. PubMed ID: 38305819
[TBL] [Abstract][Full Text] [Related]
12. A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα.
Jauslin WT; Schild M; Schaefer T; Borsari C; Orbegozo C; Bissegger L; Zhanybekova S; Ritz D; Schmidt A; Wymann M; Gillingham D
Chem Sci; 2024 Jan; 15(2):683-691. PubMed ID: 38179525
[TBL] [Abstract][Full Text] [Related]
13. The road less traveled: activating an oncogenic kinase.
Paul M; Fruman DA
Trends Pharmacol Sci; 2023 Oct; 44(10):640-642. PubMed ID: 37553270
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in treatment of follicular lymphoma: efficacy of PI3Kα/δ inhibitor (TQ-B3525).
Watanabe T
Signal Transduct Target Ther; 2024 May; 9(1):134. PubMed ID: 38755160
[No Abstract] [Full Text] [Related]
15. Structural insights into the interaction of three Y-shaped ligands with PI3Kα.
Zhou Q; Liu X; Neri D; Li W; Favalli N; Bassi G; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2304071120. PubMed ID: 37585458
[TBL] [Abstract][Full Text] [Related]
16. Correction: A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα.
Jauslin WT; Schild M; Schaefer T; Borsari C; Orbegozo C; Bissegger L; Zhanybekova S; Ritz D; Schmidt A; Wymann M; Gillingham D
Chem Sci; 2024 Jan; 15(4):1520. PubMed ID: 38274068
[TBL] [Abstract][Full Text] [Related]
17. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300.
Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ
Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of γ-secretase inhibition and modulation by small molecule drugs.
Yang G; Zhou R; Guo X; Yan C; Lei J; Shi Y
Cell; 2021 Jan; 184(2):521-533.e14. PubMed ID: 33373587
[TBL] [Abstract][Full Text] [Related]
19. Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis.
Lee JH; Kim JY; Noh S; Lee H; Lee SY; Mun JY; Park H; Chung WS
Nature; 2021 Feb; 590(7847):612-617. PubMed ID: 33361813
[TBL] [Abstract][Full Text] [Related]
20. alpha-Benzyl-N-methylphenethylamine (BNMPA), an impurity of illicit methamphetamine synthesis: pharmacological evaluation and interaction with methamphetamine.
Moore KA; Lichtman AH; Poklis A; Borzelleca JF
Drug Alcohol Depend; 1995 Aug; 39(2):83-9. PubMed ID: 8529536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
